Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Italy
· Delayed Price · Currency is EUR 53.10
-0.05 (-0.09%)
Mar 28, 2025, 2:45 PM CET
BIT:REC Revenue
In the year 2024, Recordati Industria Chimica e Farmaceutica had annual revenue of 2.34B EUR with 12.45% growth. Recordati Industria Chimica e Farmaceutica had revenue of 598.52M in the quarter ending December 31, 2024, with 13.75% growth.
Revenue
2.34B
Revenue Growth
+12.45%
P/S Ratio
n/a
Revenue / Employee
525.61K
Employees
4,450
Market Cap
10.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.34B | 259.27M | 12.45% |
| Dec 31, 2023 | 2.08B | 229.02M | 12.36% |
| Dec 31, 2022 | 1.85B | 273.23M | 17.29% |
| Dec 31, 2021 | 1.58B | 131.21M | 9.06% |
| Dec 31, 2020 | 1.45B | -32.98M | -2.23% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DiaSorin | 1.19B |
| Amplifon | 2.41B |
| Philogen | 3.92M |
| EL.En. | 148.11M |
| Pharmanutra | 115.50M |
| Garofalo Health Care | 470.71M |
| Safilo Group | 993.22M |
| GPI S.p.A. | 484.01M |
Recordati Industria Chimica e Farmaceutica News
- 6 weeks ago - There is still such a huge need to do better with rare diseases: Recordati CEO - CNBC
- 4 months ago - Angelini Pharma Said to Discuss Combination With CVC’s Recordati - BNN Bloomberg
- 4 months ago - Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase - CNBC
- 4 months ago - Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - GuruFocus
- 5 months ago - Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Recordati reports nine-month results - Seeking Alpha
- 6 months ago - Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati - Benzinga
- 6 months ago - Recordati buys rights to rare immune disorder drug from Sanofi for $825mln - Zawya